You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)

 

Online download statistics by month:

Online download statistics by month: March 2021 to March 2024

AbstractFullPdf
Mar 2021654654213
Apr 2021659659189
May 202142542554
Jun 202115715729
Jul 202113913946
Aug 202113013023
Sep 202123623641
Oct 202112712749
Nov 202113713836
Dec 202114714739
Jan 202212713043
Feb 202210410737
Mar 2022687229
Apr 2022464718
May 2022666624
Jun 2022565722
Jul 2022606214
Aug 2022879018
Sep 2022707634
Oct 2022747519
Nov 2022939537
Dec 2022686817
Jan 2023737325
Feb 2023919220
Mar 2023636425
Apr 2023666632
May 2023888926
Jun 2023828333
Jul 2023282816
Aug 2023313126
Sep 2023373731
Oct 2023434332
Nov 2023767822
Dec 2023757536
Jan 2024454621
Feb 2024464621
Mar 2024696952
Total464346771449